Daratumumab

Evidence Level: L4

Predicted Indications: 10

Daratumumab
Daratumumab: From Plasma Cell Myeloma to Indolent Plasma Cell Myeloma

## Pharmacist Assessment Report

Daratumumab: From Plasma Cell Myeloma to Indolent Plasma Cell Myeloma

One-Sentence Summary

Daratumumab is an anti-CD38 monoclonal antibody, originally used to treat plasma cell myeloma (multiple myeloma). The TxGNN model predicts it may be effective for indolent plasma cell myeloma, but only 1 clinical trial (which does not test daratumumab as the investigational drug) and 5 publications (mostly mechanistic or case reports) are linked to this direction. Direct clinical evidence is therefore very limited.

Quick Overview

Item	Content
Original Indication	Plasma cell myeloma (the Singapore licence records contain no approved indication text)
Predicted New Indication	Indolent plasma cell myeloma
TxGNN Prediction Score	98.13%
Evidence Level	L4
Singapore Market Status	✓ Marketed
Number of Registrations	3
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the data compiled for this report. Based on general knowledge, daratumumab is an antibody that targets CD38, a protein expressed at high levels on myeloma cells. Its efficacy in plasma cell myeloma is established, and mechanistically it may be applicable to indolent myeloma.

Indolent (smoldering) myeloma sits on the same disease spectrum as active myeloma. A 2017 study (PMID 28915615) showed that CD38 is expressed in the myeloma bone marrow niche, including in patients with indolent disease, which gives a biological rationale for anti-CD38 therapy.

However, the rationale is mostly mechanistic. The only linked clinical trial tests a different drug, and the literature contains no interventional data on daratumumab in this indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04136756	Phase 1	Completed	30	Dose-escalation and expansion study of NKTR-255 in relapsed/refractory haematological malignancies. Daratumumab (subcutaneous) is only a combination partner in one arm. Not an indolent myeloma study and offers no direct evidence of daratumumab efficacy.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28915615	2017	Preclinical/Translational	Oncotarget	CD38 is expressed in the myeloma bone niche, including in indolent monoclonal gammopathy. Supports a rationale for anti-CD38 therapy, including inhibition of osteoclast formation.
42488083	2026	Review	American Journal of Blood Research	Review of the multiple roles of CD38 in B-cell lymphomas; background on CD38 as a therapeutic target.
34514307	2021	Case report	European Heart Journal: Case Reports	Imaging in a patient with aortic valve papillary fibroelastoma and cardiac AL amyloidosis. Not directly relevant.
32736600	2020	Case report	BMC Gastroenterology	Disseminated crystal storing histiocytosis presenting as a colonic mass, secondary to indolent myeloma.
40257478	2025	Case report	Annals of Hematology	Paraneoplastic leukocytoclastic vasculitis as the first sign of smoldering IgG kappa myeloma.

Singapore Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
SIN16032P	DARZALEX SC Solution for Injection 1800MG/15ML	Injection, solution	Not recorded in the licence data
SIN15111P	DARZALEX Concentrate for Solution for Infusion 400MG/20ML	Infusion, solution concentrate	Not recorded in the licence data
SIN15110P	DARZALEX Concentrate for Solution for Infusion 100MG/5ML	Infusion, solution concentrate	Not recorded in the licence data

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy / immunotherapy (anti-CD38 monoclonal antibody), not a conventional cytotoxic agent
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert; typically CBC and infusion-reaction monitoring
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: The interaction screening found 81 recorded interactions. Examples classed as Major include deferiprone, samarium (153Sm) lexidronam, adalimumab, baricitinib, certolizumab pegol and cladribine. Moderate examples include zidovudine, azathioprine, ganciclovir, alemtuzumab, anakinra, chloramphenicol, roflumilast and strontium chloride Sr-89, as well as several vaccines (anthrax, tetanus toxoid, live cholera).
Practical concerns noted in the prediction analysis: Anti-CD38 therapy is known to interfere with red cell serology (blood typing and cross-matching), and it may increase infection risk through immune suppression.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high (98.13%) and the biological rationale is plausible, since indolent myeloma is on the same disease spectrum as the approved indication. However, the evidence is L4: the only linked trial tests a different drug, and the literature is mechanistic or case-report only. There is no direct clinical evidence of daratumumab efficacy or safety in indolent myeloma that would justify advancing.

To proceed, the following is needed:

Review of the package insert (warnings, contraindications and approved indications) for the Singapore licences
Detailed mechanism of action data (MOA)
Searches for interventional studies and trials of daratumumab specifically in smoldering/indolent myeloma, and a review of their results
A risk-benefit assessment for early-stage disease, including infection risk and red cell serology interference
Confirmation of the original approved indication text on the Singapore licences
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.